Stock Research for ALPMY


Featured Broker: Ally Invest

Get the due diligence for another stock.


ALPMY Stock Chart & Research Data

The ALPMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ALPMY Due diligence Resources & Stock Charts

The ALPMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALPMY Detailed Price Forecast - CNN Money CNN View ALPMY Detailed Summary - Google Finance
Yahoo View ALPMY Detailed Summary - Yahoo! Finance Zacks View ALPMY Stock Research & Analysis -

Stock Analysis

TradeIdeas View ALPMY Trends & Analysis - Trade-Ideas Barrons View ALPMY Major Holders - Barrons
NASDAQ View ALPMY Call Transcripts - NASDAQ Seeking View ALPMY Breaking News & Analysis - Seeking Alpha
Spotlight View ALPMY Annual Report - OTC Report View ALPMY OTC Short Report -
TradeKing View ALPMY Fundamentals - TradeKing Charts View ALPMY SEC Filings - Bar Chart
WSJ View Historical Prices for ALPMY - The WSJ Morningstar View Performance/Total Return for ALPMY - Morningstar
MarketWatch View the Analyst Estimates for ALPMY - MarketWatch CNBC View the Earnings History for ALPMY - CNBC
StockMarketWatch View the ALPMY Earnings - StockMarketWatch MacroAxis View ALPMY Buy or Sell Recommendations - MacroAxis
Bullish View the ALPMY Bullish Patterns - American Bulls Short Pains View ALPMY Short Pain Metrics -

Social Media Mentions

StockTwits View ALPMY Stock Mentions - StockTwits PennyStocks View ALPMY Stock Mentions - PennyStockTweets
Twitter View ALPMY Stock Mentions - Twitter Invest Hub View ALPMY Investment Forum News - Investor Hub
Yahoo View ALPMY Stock Mentions - Yahoo! Message Board Seeking Alpha View ALPMY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ALPMY - Insider Cow View Insider Transactions for ALPMY - Insider Cow
CNBC View ALPMY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALPMY - OTC Markets
Yahoo View Insider Transactions for ALPMY - Yahoo! Finance NASDAQ View Institutional Holdings for ALPMY - NASDAQ

Stock Charts

FinViz View ALPMY Stock Insight & Charts - StockCharts View ALPMY Investment Charts -
BarChart View ALPMY Stock Overview & Charts - BarChart Trading View View ALPMY User Generated Charts - Trading View

Latest Financial News for ALPMY

Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company
Posted on Wednesday April 18, 2018

TOKYO, April 18, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, "Astellas" ) and Kite, a Gilead Company (Nasdaq: GILD, President and CEO: John Milligan, "Kite"), today announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to Kite. The asset transfer was completed on April 12, 2018.

Updates on AbbVie’s AndroGel, Lupron, and Kaletra
Posted on Tuesday April 17, 2018

In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter. In fiscal 2017, AndroGel generated revenue of $577 million, marking a ~14.5% decline YoY.

Understanding FibroGen’s Research Pipeline
Posted on Friday April 06, 2018

FibroGen (FGEN) is capitalizing on its extensive experience in fibrosis and hypoxia-inducible factor (or HIF) biology to advance a pipeline targeted for the treatment of anemia, fibrotic disease, cancer, and corneal blindness. Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200. FG-3019 is a fully human monoclonal antibody that inhibits the activity of connective tissue growth factor.

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Posted on Monday March 26, 2018

TOKYO and BOTHELL, Wash., March 26, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics, Inc. (SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors (CPI). Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition.

Enter a stock symbol to view the stock details.